Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning

Last updated: October 26, 2017
Sponsor: UMC Utrecht
Overall Status: Completed

Phase

4

Condition

Neurologic Disorders

Treatment

N/A

Clinical Study ID

NCT02308332
ABR50959
  • Ages 30-50
  • Male
  • Accepts Healthy Volunteers

Study Summary

This study will evaluate the effects of switching Atripla to Eviplera on neurocognition measured by neuropsychological testing and functional MRI

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male, between 30 and 50 years

  • HIV-1 RNA < 50 copies/mL on screening visit

  • on Atripla continuously for ≥6 months preceding the screening visit

  • Have a HIV genotype prior to starting cART with Atripla with no known resistance toany of the study agents at any time in the past including, but not limited to RTmutations K65R, K101E/P, E138G/K/Q/R, Y181C/I/V, M184V/I and H221Y

  • Negative TPHA or VDRL < 12 months prior to the screening visit

  • no signs of an acute or chronic hepatitis C infection within the past 12 months beforescreening as defined in the Dutch guideline (Arends et al. Neth J Med 2011)

  • No subjective neurocognitive complaints in the preceding 12 months

  • willingness to take Eviplera together with food according to the manufacturer'sprescriptions.

  • Estimated glomerular filtration rate ≥50 mL/min (Cockcroft-Gault formula) on lastroutine measurement during outpatient clinic

  • able to understand and comply to study procedures and to provide written informedconsent

Exclusion

Exclusion Criteria:

  • Non-native Dutch speakers

  • Proven major depression through psychiatric consultation within the past year or onanti-depressant drugs (SSRI or TCA)

  • Active or known from medical history past CNS opportunistic infections

  • History of proven neurologic disease (e.g. multiple sclerosis, brain tumor,cerebrovascular event, etc)

  • Active psychiatric disorders classified according to the DMS V criteria

  • History or evidence of alcohol or drug abuse defined according to DSM V criteria

  • TSH within normal reference values on last routine measurement during outpatientclinic

  • Contraindications for undergoing an MRI; a pacemaker or metallic devices/foreignbodies in situ, proven claustrophobia.

Study Design

Total Participants: 58
Study Start date:
February 01, 2015
Estimated Completion Date:
June 30, 2017

Study Description

Efavirenz, an antiretroviral drug used for the treatment of human immunodeficiency virus 1 (HIV-1) infections, is known for its neurological and psychiatric adverse events. Efavirenz is part of Atripla®, a single tablet regimen (STR), currently the most prescribed antiretroviral drug in the Netherlands. Recently, a new STR has become available, Eviplera® containing a successor of Efavirenz, named Rilpivirin. It has been shown in the phase-3 ECHO and THRIVE studies that Atripla as well as Eviplera have excellent and comparable antiretroviral efficacy in naive HIV-infected patients. Furthermore, data from these studies have shown that Eviplera was associated with fewer neurological and psychiatric adverse events than Atripla over 48 weeks. However, this was only patient reported adverse events, not neuropsychological evaluation. Furthermore, they were treatment naïve for HIV. Moreover, there might be a bias in these kind of switch studies due to the fact that those patients who switch will mostly regard their new combination better than the old one. Contrary, data on the long term impact of Efavirenz on neuropsychological performance and symptoms are conflicting.

Objective: This study aims to investigate the effect of switching from Atripla to Eviplera on neurocognitive performances (neurocognitive testing) and imaging (functional MRI scanning) in virologically suppressed HIV-infected patients.

Connect with a study center

  • UMC Utrecht

    Utrecht,
    Netherlands

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.